This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team.
[Turku, Finland, October 9, 2024]
3PBIOVIAN, a leading contract development and manufacturing organization (CDMO), announces the appointment of Almira Bartolomé as Business Development Director for Advanced Therapies, reporting to Elena Erroba, Chief Commercial Officer of 3PBIOVIAN.
Almira brings over 12 years of experience in business development, sales, and strategic leadership within the biotech sector, having worked with international companies such as CGT Catapult, Immudex ApS, and Fujifilm Diosynth Biotechnologies, among others. In her most recent role at Fujifilm Diosynth Biotechnologies, she served as Executive Director of Business Development for Advanced Therapies and Vaccines, managing the Europe and Rest of World teams. Her extensive expertise spans immunology, advanced therapies, and recombinant proteins, and she has negotiated complex service contracts with both small biotech companies and large pharmaceutical firms. Almira’s global vision and strategic focus will be essential in driving the company’s continued growth and expansion on an international scale.
Almira Bartolomé – Business Development Director for Advanced Therapies
Almira holds a PhD in Veterinary Sciences, with research focused on vaccine development, and an MBA from Copenhagen Business School, further strengthening her expertise in corporate strategy, business development, and innovation.
Elena Erroba, Chief Commercial Officer of 3PBIOVIAN, commented: “We are thrilled to welcome Almira. Her experience will be key to further driving our growth and solidifying our position as one of the leading CDMOs in the sector, particularly in the field of advanced therapies.”
With this appointment, 3PBIOVIAN reinforces its leadership as a CDMO specializing in the development and manufacturing of biopharmaceutical products, reaffirming its commitment to excellence and strengthening its competitiveness in the European market.
About 3PBIOVIAN
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Their service offerings include protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors for adenovirus and adeno-associated virus for gene therapy, and cell therapy products. Additionally, they provide fill and finish services for recombinant proteins and viral vectors. The company has manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, efficiently supporting the diverse needs of their clients, covering everything from preclinical and clinical supply to large-scale commercial manufacturing for drug substance and drug product. https://www.3pbiovian.com